Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
No phase specified	Treatment	Closed	under 21	NCI	POG-7812 MDAR-292

Objectives

I.  Determine the antitumor activity of anguidine in the treatment of 
malignant gliomas relative to clinical response and survival.
II.  Observe for expected and unexpected adverse effects and for factors 
important in producing these effects.
III.  Determine the antitumor activity of anguidine in the treatment of 
malignant brain tumors in children and adolescents relative to clinical 
response and survival.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with histologically 
confirmed primary CNS tumors:  astrocytoma, Grades III and IV; ependymoma; 
oligodendroglioma; medulloblastoma, or patients under 21 years of age with 
recurrent brain stem glioma.  They must have a life expectancy of at least 8 
weeks, granulocyte counts over 2000, platelet counts at least 100,000 and a 
lesion measurable by scan.  They must not have had radiation or chemotherapy 
for at least 3 weeks.  Serum creatinine must not exceed 2.5 mg, nor bilirubin 
6.0 mg.  (Protocol closed to adults in February 1980 and replaced, for adults, 
by SWOG-7980.  Protocol closed to patients with astrocytoma in February 1980.)

Expected Enrollment

A minimum of 14 patients will be entered in each stratification.  Protocol 
closed March 1982.

Outline

Nonrandomized study.
Single-agent Chemotherapy.  Anguidine, ANG, NSC-141537.

Trial Contact Information

Trial Lead Organizations

Pediatric Oncology Group

Teresa Vietti, MD, Protocol chair		Ph: 314-454-6209